Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07206901 · ClinicalTrials.gov registry record · NA
Evaluation of an Ayurvedic Herbal Compound Compared to Vitamins C+E and Placebo on Vascular Function in High-Risk Subjects
A NA study, sponsored by Maharishi International University.
- Completed
- Registry status
- NA
- Development phase
- 143
- Enrollment target
NCT07206901: Completed NA study, sponsored by Maharishi International University.
NCT07206901 is a NA study that has completed, run by Maharishi International University. The registered enrollment target is 143 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07206901, a NA study, has completed, sponsored by Maharishi International University.
- COMPLETED
- Registry status
- NA
- Development phase
- 143 participants
- Enrollment target
Study Summary
This was a randomized controlled trial aimed to evaluate the effects of an herbal Ayurvedic herbal supplement in comparison to a Vitamin C/E supplement and an inert placebo on heart health. There were three treatment groups: Maharishi Amrit Kalash (MAK), vitamin C+E and the placebo group. The primary outcome was smooth muscle responsiveness, blood flow and dilation using the brachial artery reactivity test in a Black population at risk for heart disease.
Primary Outcome
This is a clinical test or protocol that measures the reactivity of the brachial artery and its ability to vasodilate in response to increased blood flow, typically assessed using ultrasound imaging. It is administered with a hyperemia phase (occlusion of the right arm with a cuff) followed by release and/or a sublingual nitroglycerin phase in which a small dose of nitroglycerin is placed under the tongue of the patient in a supine position. In each case, the flow mediated dilation (FMD) of the
Interventions
- DIETARY_SUPPLEMENT Maharishi Amrit Kalash
- DIETARY_SUPPLEMENT vitamin C + E
- OTHER Inert Placebo Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2002-10-14 |
| Est. Completion | 2014-10-27 |
| Phase | NA |
What the finished NCT07206901 record still lists
NCT07206901 is an interventional study that assigns participants to a tested intervention. The registered 143 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 3 interventions - of which Maharishi Amrit Kalash is the first listed.
NCT07206901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07206901 about?
NCT07206901 is a clinical study titled "Evaluation of an Ayurvedic Herbal Compound Compared to Vitamins C+E and Placebo on Vascular Function in High-Risk Subjects". This was a randomized controlled trial aimed to evaluate the effects of an herbal Ayurvedic herbal supplement in comparison to a Vitamin C/E supplement and an inert placebo on heart health. There were three treatment groups: Maharishi Amrit Kalash (MAK), vitamin C+E and the placebo group. The primar...
What is the current status of trial NCT07206901?
This trial is currently completed. It is a NA study. The enrollment target is 143 participants. The study started on 2002-10-14. Estimated completion is 2014-10-27.
What interventions are being tested in trial NCT07206901?
The interventions under investigation include: Maharishi Amrit Kalash (DIETARY_SUPPLEMENT), vitamin C + E (DIETARY_SUPPLEMENT), Inert Placebo Capsule (OTHER).
Who is sponsoring clinical trial NCT07206901?
This trial is sponsored by Maharishi International University, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07206901's enrollment target sits among peer trials
143 711th of 2000 higher than 1,290 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI